Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

View/Open
Revised_Manuscript_IBD_Porter_et_al_IBD_D_18_00038_clean_Combined.pdf (626.8Kb)
Publication date
15/09/2018
Author
Metadata
Show full item record
Citation
Porter , R J , Andrews , C , Brice , D P , Durum , S K & McLean , M H 2018 , ' Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease? ' , Inflammatory Bowel Diseases , vol. 24 , no. 10 , pp. 2123-2134 . https://doi.org/10.1093/ibd/izy230
URI
http://hdl.handle.net/2164/12590
DOI
https://doi.org/10.1093/ibd/izy230
Rights
This is a pre-copyedited, author-produced version of an article accepted for publication in Inflammatory Bowel Disease following peer review. The version of recordRoss John Porter, Caroline Andrews, Daniel Paul Brice, Scott Kenneth Durum, Mairi Hall McLean; Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?, Inflammatory Bowel Diseases, Volume 24, Issue 10, 15 September 2018, Pages 2123–2134., is available online at: https://academic.oup.com/ibdjournal/article/24/10/2123/5055343
Collections